Previous studies have shown that glargine/exenatide combination therapy provides glycemic and clinical benefits (weight loss and lower risk of hypoglycemia) in patients with longstanding diabetes, even when compared to basal/bolus insulin regimens3, 4, 25. This evidence concerns the gene INS and diabetes mellitus.